Search details
1.
Netrin-1 blockade inhibits tumour growth and EMT features in endometrial cancer.
Nature
; 620(7973): 409-416, 2023 Aug.
Article
in English
| MEDLINE | ID: mdl-37532934
2.
Futibatinib for FGFR2-Rearranged Intrahepatic Cholangiocarcinoma.
N Engl J Med
; 388(3): 228-239, 2023 01 19.
Article
in English
| MEDLINE | ID: mdl-36652354
3.
Lenvatinib plus pembrolizumab for patients with previously treated advanced ovarian cancer: Results from the phase 2 multicohort LEAP-005 study.
Gynecol Oncol
; 186: 182-190, 2024 May 07.
Article
in English
| MEDLINE | ID: mdl-38718741
4.
Plain language summary of the FOENIX-CCA2 study: futibatinib for people with advanced bile duct cancer.
Future Oncol
; : 1-12, 2024 Jun 17.
Article
in English
| MEDLINE | ID: mdl-38884254
5.
Qualitative evaluation of motives for acceptance or refusal of early palliative care in patients included in early-phase clinical trials in a French comprehensive cancer center: the PALPHA study.
Support Care Cancer
; 32(6): 353, 2024 May 15.
Article
in English
| MEDLINE | ID: mdl-38748187
6.
Efficacy of Selpercatinib in RET Fusion-Positive Non-Small-Cell Lung Cancer.
N Engl J Med
; 383(9): 813-824, 2020 08 27.
Article
in English
| MEDLINE | ID: mdl-32846060
7.
Safety, pharmacokinetic, pharmacodynamic and clinical activity of molibresib for the treatment of nuclear protein in testis carcinoma and other cancers: Results of a Phase I/II open-label, dose escalation study.
Int J Cancer
; 150(6): 993-1006, 2022 03 15.
Article
in English
| MEDLINE | ID: mdl-34724226
8.
First-in-human phase 1 study of budigalimab, an anti-PD-1 inhibitor, in patients with non-small cell lung cancer and head and neck squamous cell carcinoma.
Cancer Immunol Immunother
; 71(2): 417-431, 2022 Feb.
Article
in English
| MEDLINE | ID: mdl-34216247
9.
Pralsetinib for RET fusion-positive non-small-cell lung cancer (ARROW): a multi-cohort, open-label, phase 1/2 study.
Lancet Oncol
; 22(7): 959-969, 2021 07.
Article
in English
| MEDLINE | ID: mdl-34118197
10.
Autophagy as a therapeutic target in pancreatic cancer.
Br J Cancer
; 124(2): 333-344, 2021 01.
Article
in English
| MEDLINE | ID: mdl-32929194
11.
Pharmacokinetic-pharmacodynamic guided optimisation of dose and schedule of CGM097, an HDM2 inhibitor, in preclinical and clinical studies.
Br J Cancer
; 125(5): 687-698, 2021 08.
Article
in English
| MEDLINE | ID: mdl-34140638
12.
A phase 1b study of the Notch inhibitor crenigacestat (LY3039478) in combination with other anticancer target agents (taladegib, LY3023414, or abemaciclib) in patients with advanced or metastatic solid tumors.
Invest New Drugs
; 39(4): 1089-1098, 2021 08.
Article
in English
| MEDLINE | ID: mdl-33686452
13.
Avapritinib in advanced PDGFRA D842V-mutant gastrointestinal stromal tumour (NAVIGATOR): a multicentre, open-label, phase 1 trial.
Lancet Oncol
; 21(7): 935-946, 2020 07.
Article
in English
| MEDLINE | ID: mdl-32615108
14.
Phase I Study of Ramucirumab Plus Merestinib in Previously Treated Metastatic Colorectal Cancer: Safety, Preliminary Efficacy, and Pharmacokinetic Findings.
Oncologist
; 25(11): e1628-e1639, 2020 11.
Article
in English
| MEDLINE | ID: mdl-32537847
15.
Phase 1 study of the MDM2 inhibitor AMG 232 in patients with advanced P53 wild-type solid tumors or multiple myeloma.
Invest New Drugs
; 38(3): 831-843, 2020 06.
Article
in English
| MEDLINE | ID: mdl-31359240
16.
Ramucirumab plus pembrolizumab in patients with previously treated advanced non-small-cell lung cancer, gastro-oesophageal cancer, or urothelial carcinomas (JVDF): a multicohort, non-randomised, open-label, phase 1a/b trial.
Lancet Oncol
; 20(8): 1109-1123, 2019 08.
Article
in English
| MEDLINE | ID: mdl-31301962
17.
External Beam Radiation Therapy for Resectable Soft Tissue Sarcoma: A Systematic Review and Meta-Analysis.
Ann Surg Oncol
; 25(3): 754-767, 2018 Mar.
Article
in English
| MEDLINE | ID: mdl-28895107
18.
Targeting apoptosis in acute myeloid leukaemia.
Br J Cancer
; 117(8): 1089-1098, 2017 Oct 10.
Article
in English
| MEDLINE | ID: mdl-29017180
19.
Current Systemic Treatment Options for Tenosynovial Giant Cell Tumor/Pigmented Villonodular Synovitis: Targeting the CSF1/CSF1R Axis.
Curr Treat Options Oncol
; 17(2): 10, 2016 Feb.
Article
in English
| MEDLINE | ID: mdl-26820289
20.
CSF1R inhibition with emactuzumab in locally advanced diffuse-type tenosynovial giant cell tumours of the soft tissue: a dose-escalation and dose-expansion phase 1 study.
Lancet Oncol
; 16(8): 949-56, 2015 Aug.
Article
in English
| MEDLINE | ID: mdl-26179200